drugset / Trial / NCT03070301
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Phase 2
Completed
21 enrolled
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute · collabM.D. Anderson Cancer Center · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
Timeline
- Start
- 2017-02-27
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
Outcome
Missed primary endpoint
paper The study did not meet the pre-specified criteria to advance to stage two. PMID 33640871 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | — |
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Ribociclib | Small molecule | 200 mg | — |
| Subject | Ribociclib | Small molecule | 300 mg | — |